Sunny Pharmtech (ROCO:6676) Debt-to-Asset : 0.24 (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sunny Pharmtech Debt-to-Asset?

Sunny Pharmtech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$44.9 Mil. Sunny Pharmtech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was NT$341.4 Mil. Sunny Pharmtech's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was NT$1,587.4 Mil. Sunny Pharmtech's debt to asset for the quarter that ended in Dec. 2024 was 0.24.

Sunny Pharmtech Debt-to-Asset Historical Data

The historical data trend for Sunny Pharmtech's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunny Pharmtech Debt-to-Asset Chart

Sunny Pharmtech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.26

0.23

0.35

0.23

0.24

Sunny Pharmtech Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial							0.35	0.37	0.23	0.24	0.24

Competitive Comparison of Sunny Pharmtech's Debt-to-Asset

For the Biotechnology subindustry, Sunny Pharmtech's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sunny Pharmtech's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunny Pharmtech's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Sunny Pharmtech's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Sunny Pharmtech Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Sunny Pharmtech's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(44.923	+	341.374)	/	1587.37
	=	0.24

Sunny Pharmtech's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(44.923	+	341.374)	/	1587.37
	=	0.24

Sunny Pharmtech (ROCO:6676) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Sunny Pharmtech Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Sunny Pharmtech's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Sunny Pharmtech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sunny Pharmtech Inc (ROCO:6676) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.255,Longyuan 1st Road, Hsinchu Science Park, Longtan District, Taoyuan, TWN, 325002

Website

http://www.sunnypharmtech.com

Sunny Pharmtech Inc is a specialty pharmaceutical company. It is now fully-integrated, doing research, development, and manufacturing on both API and finished-dose products, which includes orals, liquids, semi-solids, and parenterals.

Sunny Pharmtech Headlines

No Headlines